2020
Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients
Miccio JA, Talcott WJ, Jairam V, Park HS, Yu JB, Leapman MS, Johnson SB, King MT, Nguyen PL, Kann BH. Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer And Prostatic Diseases 2020, 24: 414-422. PMID: 32989262, DOI: 10.1038/s41391-020-00291-3.Peer-Reviewed Original ResearchConceptsProstate cancer-specific survivalLow-risk prostate cancerExternal beam radiotherapyTreatment selection biasOverall survivalRadical prostatectomyProstate cancerOS differenceLow-risk prostate cancer patientsCancer-specific survivalEnd Results (SEER) databaseProstate cancer patientsClinical trial designEffectiveness researchComparative effectiveness researchPropensity-score matchingMethodsThe SurveillanceTreatment guidelinesResults databaseEntire cohortResultsA totalCancer patientsTreatment modalitiesNational registryPatient managementGeographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening
Yang DX, Makarov DV, Gross CP, Yu JB. Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening. Cancer Control 2020, 27: 1073274820902267. PMID: 32003227, PMCID: PMC7003204, DOI: 10.1177/1073274820902267.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancer incidenceProstate cancer incidenceHealth care service areasMetastatic diseaseCancer incidenceNational Cancer Institute's SurveillanceEnd Results (SEER) databaseLocalized prostate cancerSEER 18 registriesProstate-specific antigenPSA screeningLocalized diseaseResults databaseProstate cancerOlder menMetastatic incidenceIncidenceDiseaseDiagnosisLate changesMenRecent increaseAssociationRegistryCancer
2019
Contemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening.
Yang D, Makarov D, Gross C, Yu J. Contemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening. Journal Of Clinical Oncology 2019, 37: 1567-1567. DOI: 10.1200/jco.2019.37.15_suppl.1567.Peer-Reviewed Original ResearchProstate cancer incidenceHealth service areasMetastatic prostate cancerMetastatic prostate cancer incidenceMetastatic diseaseCancer incidenceProstate cancerLocalized diseasePopulation-weighted linear regressionMen 70 yearsEnd Results (SEER) databaseHealth Service regionResults databaseIncidence rateHospital careMetastatic incidenceIncidenceDiseaseCancerLate increasePSALinear regressionMenTemporal relationshipSurveillance
2018
Association between metastatic free interval and recurrent metastatic breast cancer survival: Findings from the Surveillance, Epidemiology and End Results database.
Chang E, Mougalian S, Adelson K, Young M, Yu J. Association between metastatic free interval and recurrent metastatic breast cancer survival: Findings from the Surveillance, Epidemiology and End Results database. Journal Of Clinical Oncology 2018, 36: e13069-e13069. DOI: 10.1200/jco.2018.36.15_suppl.e13069.Peer-Reviewed Original Research
2016
A Novel Prognostic Index for Ocular Adnexal Lymphoma
Meeks M, Park H, Yu J, Roberts K, Foss F, Wilson L. A Novel Prognostic Index for Ocular Adnexal Lymphoma. Blood 2016, 128: 3597. DOI: 10.1182/blood.v128.22.3597.3597.Peer-Reviewed Original ResearchOcular adnexal lymphomaNovel prognostic indexOverall survivalIndolent histologiesPrognostic indexRelative survivalAdnexal lymphomaGroup IIGroup IGroup I. Group IEnd Results (SEER) databaseSuperior overall survivalCohort of patientsProportional hazards analysisKaplan-Meier estimatesLacrimal gland tumorsHeterogeneous patient populationLarge national databaseAggressive histologyDistant diseaseConjunctival tumorsHazard ratioPrognostic factorsRare malignancyIndependent predictors
2015
Historical trends of radiotherapy use in prevalent malignancies over 38 years in SEER
Yeboa D, Aneja S, Montana G, Roberts K, Yu J. Historical trends of radiotherapy use in prevalent malignancies over 38 years in SEER. Journal Of Radiation Oncology 2015, 4: 11-17. DOI: 10.1007/s13566-015-0182-y.Peer-Reviewed Original ResearchIntensity-modulated radiation therapyProstate cancerRadiation therapyEnd Results (SEER) databaseAmerican Joint CommitteeBreast cancer treatmentUse of RTInitial therapyMethodsThe SurveillanceRT receiptNonmetastatic patientsResults databaseCommon malignancyTherapy utilizationColorectal cancerLung cancerPrevalent malignancyCancer sitesRadiotherapy useHigh incidenceMedical treatmentJoint CommitteeDisease sitesPersistent decreaseTherapy
2013
Changes in early- and late-stage colorectal cancer incidence during the era of screening: 1976-2009.
Yang D, Gross C, Yu J. Changes in early- and late-stage colorectal cancer incidence during the era of screening: 1976-2009. Journal Of Clinical Oncology 2013, 31: 1522-1522. DOI: 10.1200/jco.2013.31.15_suppl.1522.Peer-Reviewed Original ResearchLate-stage colorectal cancerColorectal cancerCancer incidenceLate-stage colorectal cancer diagnosisEarly-stage colorectal cancerNon-screened populationColorectal cancer incidenceEnd Results (SEER) databaseColorectal cancer incidence dataAdults 50 yearsColorectal cancer diagnosisBreast cancer screeningLate-stage cancerEarly-stage cancerCancer incidence dataColorectal screeningResults databaseCancer screeningAdults 50Curable stageSubsequent diagnosisStage cancerDetects cancerNHS dataCancer
2012
The influence of physician densities and patient characteristics on the decision to treat prostate cancer patients with varying clinical benefit.
Yu J, Aneja S, Makarov D, Roberts K, Gross C. The influence of physician densities and patient characteristics on the decision to treat prostate cancer patients with varying clinical benefit. Journal Of Clinical Oncology 2012, 30: 19-19. DOI: 10.1200/jco.2012.30.5_suppl.19.Peer-Reviewed Original ResearchHealth system factorsHealth service areasCurative therapyUrologist densityClinical benefitProstate cancerRadiation oncologistsPhysician densitySystem factorsRadiation oncologist densityEnd Results (SEER) databaseLower likelihoodReceipt of treatmentMarital statusProstate cancer patientsHigher likelihoodLogistic regression modelsArea Resource FilePatient characteristicsPatient factorsInitial treatmentResults databasePatient populationCancer patientsProper therapyThe influence of regional radiation oncologist and urologist capacities on treatment choice for prostate cancer management.
Yu J, Aneja S, Makarov D, Roberts K, Gross C. The influence of regional radiation oncologist and urologist capacities on treatment choice for prostate cancer management. Journal Of Clinical Oncology 2012, 30: 108-108. DOI: 10.1200/jco.2012.30.5_suppl.108.Peer-Reviewed Original ResearchHealth service areasOnly surgical treatmentSurgical treatmentHealth system characteristicsProstate cancer managementTreatment choiceCancer managementRadiation oncologistsRadiation oncologist densityEnd Results (SEER) databaseSeparate logistic regression modelsHealth system dataLogistic regression modelsArea Resource FileUse of RTUrologist densityHospital densityPatient factorsResults databaseSurgical interventionUrology serviceTreatment modalitiesProstate cancerNCI's SurveillanceRadiation therapy